Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 2INTERVENTIONAL

Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome

Impact of Adding Quercetin or Alpha Lipoic Acid as an Adjuvant Therapy on Clinical and Biochemical Outcomes in a Sample of Iraqi PCOS Patients

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.

Who May Be Eligible (Plain English)

Who May Qualify: - • Newly diagnosed patients should be at reproductive aged from 18-40 years. - Patients diagnosed with presence of micro polycystic ovaries at ultrasound. - Oligomenorrhea with inter-menstrual intervals longer than 35 days. - Clinical or biochemical signs of hyperandrogenism (acne, hirsutism). - Normal PRL levels. Who Should NOT Join This Trial: - • Presence of enzymatic adrenal deficiency and/or other endocrine disease, including diabetes. - Other comorbidities (such as hypertension, cardiovascular disease, or hormonal dysfunction). - Women who used oral contraceptives, hormonal therapy, or anti-lipidemic drugs. - Pregnant women. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * • Newly diagnosed patients should be at reproductive aged from 18-40 years. * Patients diagnosed with presence of micro polycystic ovaries at ultrasound. * Oligomenorrhea with inter-menstrual intervals longer than 35 days. * Clinical or biochemical signs of hyperandrogenism (acne, hirsutism). * Normal PRL levels. Exclusion Criteria: * • Presence of enzymatic adrenal deficiency and/or other endocrine disease, including diabetes. * Other comorbidities (such as hypertension, cardiovascular disease, or hormonal dysfunction). * Women who used oral contraceptives, hormonal therapy, or anti-lipidemic drugs. * Pregnant women.

Treatments Being Tested

DRUG

Quercetin

Quercetin 500 mg capsule daily after meal for three months

DRUG

Alpha Lipoic Acid 600 MG Oral Tablet

Alpha lipoic acid 600mg SR capsule daily after meal for three months period.

DRUG

MetFORMIN 500 Mg Oral Tablet

metformin 500 mg daily for three months

Locations (1)

Mustansiriyah University/ College of Pharmacy
Baghdad, Karkh, Iraq